Consumer Defensive
The Beauty Health Company(SKIN)
Live Price
Offline$0.663
+2.00% today
1Y Change
-66.11%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $110.00M
- Revenue Growth
- -10.0%
- EPS Growth
- +65.2%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The Beauty Health Company (SKIN) is a Consumer Defensive stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $0.66 and down 66.1% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -10.0%, EPS growth of +65.2%, a dividend yield of 0.0%. What stands out right now is revenue -10.0%, EPS +65.2%, free cash flow +298.1% with operating margin -6.9% and ROIC -4.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SKIN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-10.0% vs +1.7% peer median
Operating Margin
Below sector median
-6.9% vs +6.6% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 7, 2026 with an EPS surprise of +44.4% and a revenue surprise of -2.1%.
The operating picture looks softer than before
Revenue is at -10.0% and EPS is at +65.2%, with operating margin around -6.9%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +44.4% | -36.3% | -25.6% | -33.2% |
2026 Mar 12, 2026 | +14.3% | +19.8% | +9.4% | -15.3% |
2025 Nov 6, 2025 | -12.5% | +8.5% | +0.8% | +13.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SKIN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SKIN Max Drawdown
-77.95%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SKIN and SPY.
Company Overview
The Beauty Health Company
NASDAQ Capital Market
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
- Leadership
- Pedro Malha
- IPO Date
- Nov 24, 2020
- Employees
- 769
- Street Address
- 2165 Spring Street
- Mailing
- Long Beach, CA, 90806
- Region
- Long Beach, CA, US
- Reporting Currency
- USD
- Investor Line
- 800 603 4996
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 6.9
- Price/Sales
- 0.4
- Price/Book
- 1.8
Growth
- Revenue
- -10.0%
- EPS
- +65.2%
- Free Cash Flow
- +298.1%
Profitability
- Gross Margin
- 65.3%
- Operating Margin
- -6.9%
- Net Margin
- -3.2%
- ROE
- -15.4%
- ROIC
- -4.7%
Balance Sheet
- Debt/Equity
- 6.20
- Current Ratio
- 1.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.